Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TNB-486 |
Synonyms | |
Therapy Description |
TNB-486 is a bispecific T-cell redirecting antibody that binds to CD19 on tumor cells as well as CD3, and may lead to tumor cell killing and inhibition of tumor growth (Blood (2019) 134 (Supplement_1): 4070). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TNB-486 | TNB486|TNB 486|AZD0486|AZD-0486|AZD 0486 | CD19 Antibody 21 CD3 Antibody 99 | TNB-486 is a bispecific T-cell redirecting antibody that binds to CD19 on tumor cells as well as CD3, and may lead to tumor cell killing and inhibition of tumor growth (Blood (2019) 134 (Supplement_1): 4070). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06526793 | Phase II | TNB-486 | AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Not yet recruiting | USA | ESP | DEU | CAN | BRA | AUS | 2 |
NCT06137118 | Phase Ib/II | TNB-486 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia (SYRUS) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT04594642 | Phase I | TNB-486 | A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 3 |